Ken Griffin Rapt Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$2.89 - $9.38 $83,232 - $270,144	-28,800 Reduced 38.04%	46,900 $143,000
Q1 2024 May 15, 2024	BUY	$6.87 - $26.45 $452,733 - $1.74 Million	65,900 Added 672.45%	75,700 $679,000
Q4 2023 Feb 14, 2024	BUY	$11.28 - $25.46 $2,256 - $5,092	200 Added 2.08%	9,800 $243,000
Q3 2023 Nov 14, 2023	BUY	$16.34 - $24.66 $68,628 - $103,572	4,200 Added 77.78%	9,600 $159,000
Q2 2023 Aug 14, 2023	SELL	$16.06 - $21.61 $56,209 - $75,635	-3,500 Reduced 39.33%	5,400 $100,000
Q1 2023 May 15, 2023	BUY	$17.19 - $30.8 $139,239 - $249,480	8,100 Added 1012.5%	8,900 $163,000
Q4 2022 Feb 14, 2023	BUY	$16.28 - $24.6 $13,024 - $19,680	800 New	800 $15,000

125

29.3M

905K

592K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $80.7M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.